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A B S T R A C T   
 
Adrenocortical cancer (ACC) is a rare and aggressive malignancy with a poor prognosis. The overall 5-year 
survival rate of patients with ENS@T stage IV ACC is less than 15%. Systemic antineoplastic therapies have a 
limited efficacy and new drugs are urgently needed. 
Human ACC primary cultures and cell lines were used to assess the cytotoxic effect of cabazitaxel, and the role 
of P-glycoprotein in mediating this effect. 
Cabazitaxel reduced ACC cell viability, both in ACC cell lines and in ACC primary cell cultures. Molecular and 
pharmacological targeting of ABCB1/P-gp did not modify its cytotoxic effect in NCI–H295R cells, while it in- 
creased the paclitaxel-induced toxicity. Cabazitaxel modified the expression of proteins involved in cellular 
physiology, such as apoptosis and cell cycle regulation. The drug combination cabazitaxel/mitotane exerted an 
additive/moderate synergism in different ACC cell experimental models. These results provide a rationale for 
testing cabazitaxel in a clinical study. 
 
 
 
1. Introduction 
Adrenocortical cancer (ACC) is a rare disease that is often associated with a severe prognosis, due to its aggressive nature and limited re- 
sponsiveness to standard systemic therapies (Konda and Kirschner, 2016). Early diagnosis, followed by radical surgical resection and ad- juvant 
mitotane therapy are actually the only valuable options to give to the patients a chance of cure (Terzolo et al., 2014). Unfortunately, one out of four 
patients have metastatic disease at diagnosis (Puglisi et al., 2018) and most radically resected ACC patients are destined to recur with local or 
metastatic disease (Libé et al., 2015). In these pa- tients, a large prospective multicenter randomized clinical trial (FIRM- ACT trial) has 
demonstrated the superiority of etoposide, doxorubicin, cisplatin and mitotane (EDP-M) regimen over the association of strep- tozotocin and 
mitotane (Sz-M) in terms of progression free survival and overall survival (Berruti et al., 2008; Fassnacht et al., 2012). The effi- cacy of EDP-M, 
however, is modest and almost all treated patients are destined to progress and die of disease. Second line therapies in ACC 
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patients with disease progression to EDP-M, such as the combination of gemcitabine plus capecitabine, are poorly efficacious (Henning et al., 2017; 
Sperone et al., 2010). Taxanes, docetaxel and paclitaxel, are an important class of antineoplastic agents used in the treatment of a wide variety of 
cancers. The most known mechanism of action of taxanes is as microtubule stabilizer since they shift the equilibrium between so- luble tubulin and 
the microtubule polymer in favor of the latter, and thereby reduce the critical concentration of tubulin required to form a microtubule (reviewed in 
Rohena and Mooberry, 2014). Other me- chanisms of action have been afterward proposed, owing the capability to: 1) block the microtubule 
disassembly in chromosome separation; 2) modify cell cytoskeleton, with an impact on cellular functions, as many cell components move along  
microtubules; 3) directly act on trascrip- tional activity, inducing apoptosis (von Haefen et al., 2003; Komlodi- Pasztor et al., 2011; Fitzpatrick and 
de Wit, 2014). Increasing evidence propose that the clinical efficacy of taxanes is mainly due to their in- hibition of duplication mechanisms in the 
cell cycle interphase invol- ving microtubules, rather than their effect on mitosis (Fitzpatrick and de Wit, 2014). Due to these multi-modal 
mechanisms of action, taxanes can be potentially efficacious in the management of ACC patients. However, published clinical trials did not support 
their efficacy in this contest since a phase II trial testing the combination of cisplatin plus docetaxel as first line therapy in advanced ACC (Urup et 
al., 2013) showed an inferior activity of this regimen as compared to EDP-M (Berruti et al., 2005). Furthermore, a phase II trial exploring the asso- 
ciation of paclitaxel and sorafenib as second line therapy in ACC pa- tients progressing to EDP-M was interrupted prematurely due to in- efficacy 
(Berruti et al., 2012a). One of the most important mechanism limiting the efficacy of many chemotherapeutic drugs including taxanes in ACC 
(Lockhart et al., 2003) is the great expression of the ATP binding cassette subfamily B member 1 (ABCB1) (Bates et al., 1991; Villa et al., 1999). The 
ABCB1 gene encodes the P-glycoprotein (P-gp) that med- iates multidrug resistance in cell culture by increasing efflux of che- motherapeutic 
agents, thus decreasing their intracellular accumulation (Chen and Sikic, 2012). 
Cabazitaxel is a new semisynthetic taxane, dimethyl derivate of docetaxel, bearing methoxy groups in place of hydroxyl groups in the side chain 
at positions C-7 and C-10, that is efficacious in ABCB1 ex- pressing tumors (Kathawala et al., 2015). Resistance to first-generation taxanes is 
frequently observed in different tumor types, resulting in treatment failure. This finding stimulated large-scale preclinical screening process, in order 
to identify a taxane-like drug, efficacious also in docetaxel- and paclitaxel-resistant tumors. In both docetaxel-sensitive and docetaxel-resistant cell 
lines, the chemical structure of cabazitaxel resulted in the greatest increase in in vitro potency, without significantly increasing toxicity at the 
maximum tolerated dose, in contrast to other side chain modifications (Vrignaud et al., 2013). The structure of cabazitaxel confers two advantages 
over old-taxanes: the poor affinity for P-gp and a marked increase of lipophilicity, that makes this drug able to easily cross the cell membrane and 
superior in pene- tration of the blood-brain barrier in preclinical models (Vrignaud et al., 2013; Azarenko et al., 2014). In a large prospective 
multicenter clinical trial involving metastatic castration-resistant prostate cancer patients who progressed to docetaxel, cabazitaxel treatment was 
associated with an increased survival over the standard therapy (mitoxantrone plus prednisone) (de Bono et al., 2010). Based on the result of this 
clinical study, cabazitaxel became a standard therapy in the management of patients with metastatic castration-resistant prostate cancer, previously 
treated with a docetaxel. The activity of cabazitaxel against several malignancies is currently tested in clinical trials (www.clinicaltrials. gov). The 
high expression of P-gp in ACC cells and the lyophilic milieu of these tumors, provide a strong rationale for testing this drug in ACC. The present 
preclinical study was designed to evaluate the in vitro preclinical effects of cabazitaxel in ACC cell lines and in human ACC primary cell cultures 
obtained from patients with ACC who underwent surgery. 
 
Table 1 
Clinical  and immunohistochemical  characteristics of ACC patients.  
 
hypersecretion 
 
Male 
59 yr old 
ACC06-I 
Male 
42 yr old 
ACC 
 
Hepatic 
metastasis 
20% 
 
Mitotic index: 18/50 HPF Ki67: 
20% 
 
 
Stage IV, multiple metastases  No secretion 2+ 0 
ACC08 
Female 
50 yr old 
ACC16 
Male 
55 yr old 
Lung metastasis Oncocytic features, mitotic index: 
10/50 HPF; Ki67: 20% 
 
Primary ACC Mitotic index: 10/50 HPF; Ki67: 
50% 
Stage IV, lung and bone 
metastases 
Stage IV, Lymphonodal 
dissemination 
No secretion 1+ 0 
 
Cortisol 3+ 2+ 
ACC29 
Female 
51 yr old 
ACC32 
Male 
66 yr old 
Primary ACC Mitotic index: 2/50 HPF; Ki67: 
< 5% 
 
Primary ACC Mitotic index: > 5/50 HPF; Ki67: 
20% 
Stage IV, lung metastases Cortisol 2+ 1+ 
 
Stage II No secretion 1+ 2+ 
 
 
 
      
       
 
  
 
 
 
 
Fig. 1. Cytotoxic effects of taxanes in primary cell cultures derived from ACC patients. Cells were treated with increasing concentration of each taxane (0.1–100 nM) 
for 4 days. Cell viability was analyzed by MTT assay. Results are expressed as percent of viable cells ± SEM; *P < 0.001 vs untreated cells; #P < 0.05 vs untreated 
cells. 
 
 
 
 
 
 
2. Materials and methods 
2.1. Cell culture 
Human ACC primary cells were derived from six patients submitted to surgical removal of primary or metastatic ACC. Their clinical char- 
acteristics are summarized in Table 1 and an immunohistochemistry characterization is shown in Supplemental Fig. 1. The local Ethical Committee 
approved the project and written informed consent was obtained from all patients. Primary cultures were obtained as pre- viously described 
(Fiorentini et al., 2016; Fragni et al., 2019), with modifications. Briefly, dissociated tumor cells were purified from cells of other origin using the 
tumor isolation kit from Miltenyi Biotec (Bo- logna, Italy). Accordingly to the manufacturer instructions, non-tumor cells were magnetically 
labeled with a cocktail of antibodies conjugated with MACS™ microbeads, then the cell suspension was loaded onto a MACS column in the 
MACS separator. The magnetically labeled non- tumor cells were retained within the column, while the tumor cells were collected, washed in 
PBS and plated in the NCI–H295R cell complete medium (see below). Primary cell cultures were then char- acterized as of adrenal origin, 
measuring the Steroidogenic Factor 1 gene expression (Sbiera et al., 2010; Hantel et al., 2016) by q-RT-PCR. The human NCI–H295R, HAC-15 (a 
subclone of NCI–H295R cells) and SW13 cell lines were obtained from the American Type Culture Col- lection (ATCC) and cultured as suggested. 
MUC-1 cell line was kindly given by dr. Hantel and cultured as indicated in Hantel et al., 2016. NCI–H295R cells were established from a 
secreting human ACC and represented the most widely used experimental cell model to study ACC in vitro (Rainey et al., 2004). HAC-15 cells derived 
from NCI–H295R cell line and retain the ACTH-sensitivity (Parmar et al., 2008). MUC-1 cells derive from a neck metastasis of EDP-M treated 
patient (Hantel et al., 2016). The SW-13 cell line has been established from a small cell car- cinoma in the adrenal cortex. These cells do not 
produce steroids and their exact histopathologic characteristics are still under investigation (Wang and Rainey, 2012). 
 
2.2. Immunohistochemistry 
Human tissue samples were obtained from formalin-fixed and par- affin embedded blocks. Sections (1.5 µm) were used for routine hae- matoxylin and 
  
 
 
eosin (H&E) staining and immunohistochemistry as previously described (Cominelli et al., 2015). The following primary antibodies and dilutions were 
used: SF1 (Abcam AB217317, 1:500), P-  gp (F4) (Thermo Fisher MAB-13854, 1:50). Heat induced antigen re- trieval treatment was performed by 
incubation for 15′ either in mi- crowaves or Thermo-bath in EDTA buffer pH 8.0. Depending on the primary antibodies used sections were incubated with 
Rat-on-Mouse HRP-Polymer (Biocare Medical) or MACH 1™ Universal HRP Polymer Kit (Biocare Medical) and reactions developed in Biocare's  
Betazoid  DAB and nuclei counterstained with haematoxylin. Digital images were acquired by an Olympus XC50 camera mounted on a BX51 
microscope (Olympus, Tokyo, Japan) with CellF Imaging software (Soft Imaging System GmbH, Münster, Germany). 
2.3. Cell treatments 
Cells were treated with increasing concentrations of cabazitaxel, docetaxel and paclitaxel. Preliminary experiments of concentration-re- sponse 
curves and time-course were conducted in the ACC cell lines, in order to establish both the optimal drug concentration range and the treatment 
length for each cell line, as indicated in the legend of Fig. 2. ACC primary cell cultures were treated for 4 days with a range of concentrations 
between 0.1 and 100 nM of each taxane. The P-gp in- hibitor tariquidar was solubilized in DMSO and tested in the range of concentrations from 10 
to 100 nM (Mistry et al., 2001). When required by the experimental design, ACC cells were pre-treated with tariquidar (10 nM) for 1 h and then 
cabazitaxel or paclitaxel were added to the medium for 4 days. Drugs were purchased from Selleckchem Chemicals (DBA Italia, Segrate, MI, Italy). 
2.4. Measurement of cell viability 
Cell viability was assessed by 3-(4,5-Dimethyl-2-thiazol)-2,5-di- phenyl-2H-tetrazolium bromide (MTT) dye reduction assay. Briefly, untreated 
and taxane-treated cells were incubated with MTT dye (at final concentration of 0.5 mg/mL) and solubilized by DMSO, as pre- viously described 
(Arrighi et al., 2011). Absorbance was determined at 540/620 nm by a spectrophotometer (GDV, Rome, Italy). 
Cell viability was measured as well using the luminescence assay ATPlite™ (PerkinElmer), that measures the ATP production of viable cells. 
Cells were plated at the density of 6 × 103 cells/well in 96 wells plate; untreated and drug-treated cell viability was measured accord- ingly to the 
manufacturer instructions. 
 
 
 
 
Fig. 2. Concentration-response curves of taxane-induced inhibition of cell viability in ACC cell lines. (a): NCI– H295R cells were treated for 4 days with 0.05–500 nM concentrations of each 
taxane. *P < 0.05 vs untreated cells for each concentration from 5 nM onwards for cabazitaxel and from 10 nM onwards for docetaxel and paclitaxel. (b): HAC-15 cells (a subclone of NCI–H295R 
cells) were treated for 4 days with 2.5–100 nM cabazitaxel and docetaxel and 5–500 nM paclitaxel. 
*P < 0.05 vs untreated cells for 5 nM cabazitaxel concentration onwards, from 7.5 nM docetaxel concentration onwards, at 250 nM and 500 nM paclitaxel P was significant vs untreated 
cells. (c): MUC-1 cells were treated for 4 days with 0.05–500 nM concentrations of each taxane. *P < 0.05 vs untreated cells for each concentration from 7.5 nM onwards for cabazitaxel 
and docetaxel and from 10 nM onwards for paclitaxel. Cell viability was measured by MTT assay and/or by ATPlite. Data are the mean ± SEM of three different experiments, each point 
run in triplicate. 
 
2.5. ABCB1 gene silencing by interference RNA 
A small interfering RNA (siRNA) duplex targeting regions of ABCB1 gene and a non-targeting negative control siRNA (si-control) were used 
(Silencer®	 Select Pre-Designed siRNAs, LifeTechnologies, Milan, Italy). The si-ABCB1 sense and anti-sense sequences were: 5′-CGAUACAUGG 
UUUCCGAUTT-3′ and 5′- AUCGGAAAACCAUGUAUCGGA-3’ (si-ABCB1 
10419). NCI–H295R cells were transfected with si-ABCB1 or si-control using the Lipofectamine RNAiMAX system (LifeTechnologies, Milan, Italy) 
according to the manifacturer's instructions. 
2.6. Quantitative RT-PCR (qRT-PCR) 
Gene expression was evaluated by qRT-PCR (ViiA7, Applied Biosystems, Milan, Italy) using SYBRGreen as fluorochrome, as de- scribed 
elsewhere (Sigala et al., 2008). Sequences of oligonucleotide primers were reported in Supplemental Table 1. Reactions were per- formed under the 
following conditions: 1 cycle at 95 °C for 10 min, 40 cycles at 95 °C for 15 s, 62 °C for 1 min. Differences of the threshold cycle (Ct) values 
between the β actin housekeeping gene and the gene of interest (ΔCt) were then calculated, as an indicator of difference in the amount of mRNA  
  
 
 
 
expressed (Livak and Schmittgen, 2001). 
2.7. Western blot 
Whole cells lysate was prepared in ice-cold buffer with protease and phosphatase inhibitor cocktails (Roche, Milan, Italy), as previously described 
(Fiorentini et al., 2014). Briefly, proteins were separated by electrophoresis on a 4–12% NuPAGE bis-tris gel system (Life Technol- ogies, Milan, Italy) 
and electroblotted to a PDVF membrane. Mem-  branes were reacted using P-gp (Life Technologies, Milan, Italy), AKT, p-AKT (Cell Signaling 
Technologies, Milan, Italy), α-tubulin (Sigma Italia, Milan, Italy) and GAPDH (Merk Millipore, Burlington, MA, USA) primary antibodies, according to 
the manifacturer's instructions. Sec- ondary HRP-labeled anti-mouse and anti-rabbit antibodies (Santa Cruz Biotechnologies, Heidelberg, Germany) were 
used and the  specific  signal was visualized using an ECL PLUS Western blotting detection system (Euroclone, Milan, Italy). Densitometric analysis of the 
im- munoblots was performed using GelPro Analyzer software (Media Cy- bernetics, Silver Spring, MD, USA). 
2.8. Drug combination experiments 
Combination experiments were performed to evaluate the interac- tion of cabazitaxel with mitotane on cell viability, according to the Chou and 
Talalay method (Chou and Talalay, 1984). Cells were treated for 4 days with cabazitaxel (NCI–H295R cells: 1.8–120 nM; ACC29 and ACC32 cells: 
2–128 nM or MUC-1 cells: 2.5–160 nM) and mitotane alone (NCI–H295R cells: 0.19–12 µM; ACC29 and ACC32 cells:  0.75–48 µM; MUC-1 
cells: 1.25–80 µM) or with cabazitaxel in combi- nation with mitotane at a fixed ratio (cabazitaxel: mitotane = 1:100; 1:375; 1:500), as 
recommended for the most efficient data analysis (Chou, 2006). Cells were analyzed for cell viability using MTT assay and/or ATPlite™. Data were 
then converted to Fraction affected (Fa, range from 0 to 1 where Fa = 0 indicating 100% of cell viability and Fa = 1 indicating 0% of cell viability) 
and analyzed using the Com- puSyn software (ComboSyn inc. Paramus, NJ, USA) to calculate the Combination Index (CI). A CI value < 1, = 1 
and > 1 indicates sy- nergism, additive effect and antagonism respectively. 
2.9. Proteome Profiler Human Apoptosis array 
The protein array kit (R&D Systems, Space Import-Export, Milan, Italy) was used to detect simultaneously the expression level of 35 
apoptosis-related proteins, as previously described (Fragni et al., 2016). Briefly, membranes containing immobilized antibodies, were blocked with 
BSA for 1 h at room temperature and then incubated with un- treated and taxane-treated NCI–H295R cell lysates (400 µg/membrane) overnight at 
4 °C. After extensive washes, streptavidin-horseradish peroxidase and Chemi reagent mix were used to reveal apoptosis-re- lated proteins by 
chemiluminescence. Pixel density was analyzed using ImageJ software (National Institutes of Health: Bethesda, MD, USA). 
2.10. Double staining AO/EtBr 
NCI–H295R cells were treated with 11 nM cabazitaxel for different times. A double staining with acridine orange (AO) and ethidium bro- mide 
(EtBr) was performed to visualize and quantify the number of viable, apoptotic and necrotic cells, as described in Fragni et al. (2019). Cells were 
examined by a Zeiss LSM 510 META confocal laser-scanning microscope (Carl Zeiss AG, Germany). Several fields, randomly chosen, were 
digitalized and scored by using the NIH Image J software. 
2.11. Cell cycle analyses 
Flow cytometric cell cycle analysis was performed as described in Fragni et al. (2016). Briefly, untreated and cabazitaxel-treated NCI–H295R 
cells were fixed, treated with RNase A (12.5 µg/ml), stained with propidium iodide (40 µg/ml) (Sigma Italia, Milan, Italy) and analyzed by Flow 
Cytometry using a MACS Quant Analyzer (Mil- tenyi Biotec GmbH) for cell cycle status. Data were analyzed using FlowJo (TreeStar). 
2.12. Statistical analysis 
The analysis of the data was carried out by the GraphPad Prism version 5.02 software (GraphPad Software, La Jolla, CA), using the one- way 
ANOVA, with a post hoc test (Bonferroni's test) for multiple comparisons, considering P < 0.05 as threshold for significant differ- ence. IC50 values 
for each drug were calculated by non-linear regression of  the  concentration–response  curves.  Data  are  expressed  as   mean ± SEM of three 
independent experiments, unless otherwise specified. Cytotoxicity experiments were carried out at least three times, each point run in triplicate. 
Experiments with primary cell cul- tures were sometimes carried out twice with each point run in tripli- cate, due to the limited number of cells 
available, except for ACC29 and ACC32 cells. 
  
 
 
 
Table 2 
Efficacy of taxanes in human ACC primary cell cultures.  
Primary cell cultures maximum % of cell viability 
 
    
cabazitaxel paclitaxel docetaxel 
 
 
ACC03 28.4 ± 0.8 39.1 ± 1.5 48.7  ± 0.9 
ACC06-I 84.4 ± 1.7 70.5 ± 3.8 77.2  ± 4.6 
ACC08 43.6 ± 0.9 70.4 ± 2.7 74.7  ± 0.5 
ACC16 38.2 ± 4.4 76.7 ± 0.6 62.1  ± 2.8 
ACC29 19.1 ± 0.1 42.0 ± 0.9 21.6  ± 0.4 
ACC32 10.3 ± 0.3 40.8 ± 0.9 26.2  ± 0.8 
 
 
Results are expressed as percent of cell viability of each ACC primary culture exposed to 100 nM of each taxane ± SEM. 
 
3. Results 
3.1. Cabazitaxel induced cytotoxicity in ACC primary cell cultures 
Primary cells were exposed to increasing concentrations of currently available taxanes (paclitaxel, docetaxel and cabazitaxel) for 4 days and 
analyzed for cell viability. Each taxane exerted a concentration-de- pendent inhibition of human ACC primary cell viability (Fig. 1), how- ever, due 
to the different patient tumor stage and ACC cell character- istics, paclitaxel, docetaxel and cabazitaxel displayed a different cytotoxic efficacy in 
the primary cell cultures (Table 2). Cabazitaxel induced a greater cytotoxic effect than both paclitaxel and docetaxel in all primary cell cultures with 
the exception of ACC06-I cells, where an effect, although moderate, was observed only at high concentrations. Noteworthy, almost no ACC29 and 
ACC32 cells viable cells were de- tected at cabazitaxel concentration of 100 nM. No differences in the sensitivity to cabazitaxel cytotoxicity were 
found in hormone secreting ACC primary cells (ACC16 and ACC32) versus not secreting cells (ACC03, ACC06-I, ACC08, ACC29). 
 
3.2 Taxanes reduced cell viability of ACC cell lines 
 
The available ACC cell lines NCI–H295R, HAC-15 and MUC-1 cells were exposed to increasing concentrations of each taxane and analyzed by 
MTT and/or ATP lite assay. Results were reported in Fig. 2 and the calculated IC50 values were shown in Table 3. In each cell line, taxanes induced 
cytotoxicity, with the calculated IC50 value for the single drug revealing an order of potency that was for NCI–H295R and HAC-15 cell lines: 
cabazitaxel > docetaxel > paclitaxel, with differences among the cell lines. In particular, paclitaxel-induced cytotoxicity in the HAC- 15 cell line 
was observed only at high concentrations. Experiments conducted with the MUC-1 cell line revealed an order of potency that was: docetaxel ≥ 
cabazitaxel > paclitaxel, although the efficacy did not reach the 100% of cytotoxicity: indeed, the maximum cytotoxic effect of about 50–
60% of cytotoxicity was reached at 100 nM for each taxane and did not increase with higher drug concentrations, thus re-vealing that taxanes, 
including cabazitaxel, presented high potency but a limited efficacy in MUC-1 cells. Due to its uncertain histopathological origin, SW13 cell line 
was used as internal negative control (Wang and Rainey, 2012): each taxane displayed very similar concentration-re- sponse curves in SW13 
(Supplemental Fig. 2A). 
 
3.3 The cytotoxic effect of cabazitaxel is not influenced by P-gp expression 
To assess the role of P-gp in modulating the taxane response, we took advance of the RNA interference technique to silence the ABCB1 gene in 
NCI–H295R cells. Results showed that transfection with si- ABCB1 (100 nM) down-regulated ABCB1 mRNA after 2 days of ex- posure (76 ± 
1.9% vs si-control treated cells). ABCB1 mRNA levels were unaffected by treatment with si-control, indicating the specificity of silencing 
sequences. Exposure of NCI–H295R cells to si-ABCB1 for 6 days resulted in ABCB1 down regulation at the P-gp protein level of about 95 ± 1.7% 
vs si-control (Fig. 3a). The effect of ABCB1 knock down on cell viability was then investigated in 100 nM si-ABCB1- treated NCI–H295R cells 
for 2 days and then exposed to cabazitaxel or paclitaxel (chosen as reference drug for the first generation taxanes), at their IC50 value for 4 days. 
Silencing NCI–H295R cells with si-ABCB1 significantly increased the cytotoxicity induced by paclitaxel: + 
37.3 ± 1.3% vs paclitaxel-treated cells without si-ABCB1. Conversely, the cytotoxicity of cabazitaxel did not appear to be affected by ABCB1 
knock down (Fig. 3b). 
The non-dependence of cabazitaxel on the P-gp protein, observed with the molecular approach of the RNA interference in NCI–H295R cells 
was confirmed also in other ACC cells, with a pharmacological approach with the P-gp inhibitor tariquidar. 
ACC cell lines NCI–H295R and MUC-1 as well as two primary cell cultures, ACC29 and ACC32 cells were exposed to 10 nM tariquidar and then 
cabazitaxel or paclitaxel (at their respective IC50 for each drug in each ACC cell line or ACC primary cell culture) were added, according to the 
protocol. The ABCB1 expression was investigated by q-RT-PCR and by Western blot in ACC cells and results are reported in Supplemental Fig. 3. 
The two primary cell cultures expressed high level of both the ABCB1 gene and the P-gp, while the ΔCt obtained for MUC-1 revealed a low ABCB1 
gene expression, which translation into protein was not detectable by Western blot. Preliminary experiments have been conducted in order to 
  
 
 
 
 evaluate the effect of tariquidar on cells: exposure of up to 100 nM tariquidar for 4 days did not influence ACC cell via- bility (Supplemental 
Fig. 4). The cytotoxic effect of cabazitaxel was independent of P-gp protein expression in NCI–H295R, ACC29 and ACC32 cells; conversely, 
inhibition of P-gp activity significantly in- creased the cytotoxicity induced by paclitaxel (Fig. 4A, C, D). The MUC- 1 cells did not modify their 
sensitivity to cabazitaxel, thus suggesting that its effect was independent of P-gp activity, while we observed an increase of cytotoxic effect elicited 
by paclitaxel in tariquidar-treated cells that did not reach a statistically significant value, in line with the lack of P-gp detection by Western blot 
(Fig. 4B). Concerning SW13, both our q-RT-PCR and Western blot results (Supplemental Fig. 3) confirmed that these cells did not express ABCB1 
gene (Gagliano et al., 2014) and no effect of tariquidar was observed in SW13 cell line ex- posed to paclitaxel (Supplemental Fig. 2B). 
 
Table 3 
Taxanes IC50 values in ACC cell lines.  
 
Cell line CABAZITAXEL PACLITAXEL DOCETAXEL 
NCI–H295R 10.9 nM (95% CI: 8.1 to 14.7) 58.7 nM (95% CI: 27.2 to 127.8) 34.5 nM (95% CI: 19.9 to 59.7) 
HAC-15 6.0 nM (95% CI: 4.5 to 8.1) ambiguous 13.8 nM (95% CI: 8.7 to 21.0) 
MUC-1 4.4 nM (95% CI: 3.5 to 5.5) 34.7 nM (95% CI: 21.9 to 55.0) 3.9 nM (95% CI: 2.9 to 5.3) 
The IC50 is the mean of three independent exepriments run in triplicate. The 95% Confidence Interval (95% CI) is reported. 
 
 
 
 
 
 
 
 
 
Fig. 3. (a) ABCB1 silencing in NCI–H295R cells was detected by Western blot assay. Human α-tubulin was use 
 
 
Fig. 3. (a)ABCB1 silencing in NCI-H295R cells was detected by Western blot assays. Human a-tubulin was used as internal control. A representative blot is shown; (b) no- silencing cells 
and si-ABCB1 treated NCI–H295R cells were exposed to taxanes (IC50 value) for 4 days. Cell viability was measured by MTT assay. Results are ex- pressed as percent of viable cells ± 
SEM. Data are the mean of three different ex- periments, each point run in triplicate. 
*P < 0.001  vs  untreated  cells  (ctrl);  #P < 0.001 vs taxanes-treated cells without si-ABCB1. 
 
3.4 Cabazitaxel enhanced cytotoxicity induced by mitotane in ACC cell models 
To evaluate whether cabazitaxel treatment of ACC cells could en- hance the cytotoxicity of mitotane, the Chou-Talalay approach to study in 
vitro drug combination was applied and the CI value was calculated. We assessed the combined treatment effect in NCI–H295R cells, MUC- 1 cells 
and in two primary cultures, ACC29 and ACC32 cells. Cells were exposed to cabazitaxel and mitotane alone or in combination, with a fixed molar 
ratio (cabazitaxel: mitotane = 1:100 in NCI–H295R cells; 1:500 in MUC-1 cells and 1:375 in ACC29 and ACC32 cells) for 4 days. Dose and effect 
data obtained were then converted to Fa values and analyzed with CompuSyn software. The Fa – CI values for experimental points are reported in 
Supplemental Table 2. The results indicated that cabazitaxel and mitotane combination exerted synergism with CI range 0.43–0.96 for Fa = 0.55–
0.86 and an additive effect for Fa = 0.34 in NCI–H295R   cells;   synergism   with   CI    range    0.51–0.88    for Fa = 0.18–0.96 and an additive 
effect for Fa = 0.76 and Fa = 0.88 in ACC29; synergism with CI range 0.64–0.89 for Fa = 0.03–0.99, an additive effect  for  Fa = 0.91  and  a  
slight  antagonism  effect  for  Fa = 0.03 and Fa = 0.75 in ACC32, as shown by the Fa – CI plots (Fig. 5). MUC-1 cells were resistant to mitotane 
(Fig. 6), thus the combination analysis could not be conducted. The concentration curves of mitotane alone, cabazitaxel alone and the combination 
obtained in ACC cell lines and in ACC primary cultures are shown in Fig. 6. The isobolograms are shown in Supplemental Fig. 5. 
 
 
 
 
  
 
 
 
 
 
Fig. 4. ACC cells were pre-treated with 10 nM of tariquidar for 1 h and then IC50 value of cabazitaxel or paclitaxel was added to the medium for 4 days. Cell viability was analyzed by MTT 
assay. Results are expressed as percent of viable cells ± SEM; *P < 0.001 vs untreated cells (ctrl); #P < 0.001 vs paclitaxel-treated cells without tariquidar. 
 
 
Fig. 5. Combination Index plot. Effect of the combination of cabazitaxel and mitotane on NCI–H295R cell viability (a), ACC29 (b) and ACC32 (c). Cells were treated with increasing 
concentrations of cabazitaxel and mitotane alone or in combination at fixed concentration molar ratio (cabazitaxel: mitotane; 1: 100 in NCI–H295R cells; 1:375 in ACC29 and ACC32 cells), 
for 4 days, as described in Materials and Methods. Cell viability was measured by MTT and/or ATPliteTM assay. Dose and effect data obtained were then converted to Fa values and analyzed 
with CompuSyn software. 
  
 
 
 
Fig. 6. Concentration-response curves of cabazitaxel, mitotane and drug combination in ACC cells. ACC cells were exposed to increasing concentrations of caba- zitaxel and mitotane alone 
or in combination at fixed concentration cabazitaxel: mitotane: NCI–H295R cells, 1:100 M ratio, ACC29 and ACC32 cells: 1:375 M ratio; MUC-1 cells: 1:500 M ratio, for 4 days. Data are 
expressed as percent of viable cells vs. control (ctrl) cells. Data are the mean ± SEM of three experiments performed in triplicate. #P < 0.05 vs untreated cells; *P < 0.01 vs untreated cells. 
 
3.5 Cabazitaxel induced apoptosis of NCI–H295R cells 
To investigate molecular basis of cell death induced by cabazitaxel, we carried out the Proteome Profiler Human Apoptosis array. NCI–H295R 
cells were exposed to IC50 cabazitaxel for 1 day, to in- vestigate the early stages of apoptosis induction. A representative blot image is shown in 
Supplemental Fig. 6. The clustering analysis based on protein function (Table 4), shows that cabazitaxel exposure influenced the expression of 
proteins involved in various aspect of cellular phy- siology in NCI–H295R cells. Cabazitaxel induced an increase of pro- apoptotic proteins, such as 
Bad, Bax, Cytochrome C and (S15)-phospho- p53, involved in the intrinsic apoptotic pathway. Furthermore, the extrinsic apoptosis pathway could 
as well play an important role in mediating cabazitaxel-induced cell death, as an increase of Death Re- ceptors family proteins has been observed. 
Cabazitaxel exposure acti- vated as well some anti-apoptotic proteins and molecules involved in adaptative response to stress. The functional effect 
on apoptosis elicited by cabazitaxel on NCI–H295R cells was investigated by AO/EtBr staining. Fig. 7A and Supplemental Table 3A show that 
cabazitaxel significantly increased the number of apoptotic cells (yellow columns) compared to viable (green columns) after 4 days of treatment. At that  
time, an increase of necrotic cells could  be observed  as well,  although the difference was not statistical significant. A representative  image of cell 
acquired fields is showed in Supplemental Fig. 7. Cabazitaxel in- duced also a significant increase of p21/CIP1/CDKN1A and p27/Kip1 proteins involved 
in cell cycle arrest, indeed the analyses  of  the  cell cycle progression by flow cytometry in untreated  and  cabazitaxel-  treated NCI–H295R cells 
revealed a significant cell accumulation in the   S phase after 4 days of treatment (Fig. 7B). Furthermore, according to results presented above, after 4 
days of cabazitaxel exposure, we reported an increased the proportion of cells in the sub-G0 phase, suggestive of DNA fragmentation (Supplemental 
Table 3B). Cabazitaxel also reduced the level of the p-Akt (−45% ± 2.37; P < 0.01vs un- treated cell) in NCI–H295R cells, leaving the total Akt 
unaffected  (Fig. 8). This observation suggests that the PI3K/Akt pathway could mediate, at least in part, the cytotoxicity induced by cabazitaxel. 
  
 
 
Table 4 
Proteome Profiler Human Apoptosis array in untreated (C) and ca- 
bazitaxel-treated (T) NCI–H295R cells.  
CABAZITAXEL 
Fold Change (T vs C) 
 
 
Pro-apoptotic proteins 
Bad 2.6  ± 0.2* 
Bax 2.9  ± 0.1* 
Cleaved caspase-3 3.8  ± 0.7* 
Cytochrome C 2.5  ± 0.2* 
Phospho-p53 (S15) 11.3 ± 0.9** 
Death Receptors signaling 
TRAIL R1/DR4 1.7  ± 0.1* 
TRAIL R2/DR5 1.8  ± 0.1* 
FADD 2.5   ± 0.1* 
Fas/TNFRSF6/CD95 2.4  ± 0.1* 
Adaptative response to stress 
HO-1/HMOX1/HSP32 3.0  ± 0.6* 
HSP70 2.1  ± 0.6* 
PON2 5.4 ± 0.63** 
Anti-apoptotic proteins 
Bcl-2 2.0  ± 0.2* 
cIAP-1 2.0  ± 0.2* 
cIAP-2 2.7  ± 0.6* 
Clusterin 3.1  ± 0.1* 
Livin 1.9  ± 0.9* 
Cell cycle regulation 
p21/CIP1/CDKN1A 13.0 ± 0.9** 
p27/Kip1 4.6 ± 0.8** 
 
 
Data are expressed as fold change ± SEM. Only significant results 
were considered (*P < 0.05; **P < 0.01). 
 
 
 
 
4 Discussion 
Mitotane either alone or in association with chemotherapy (EDP-M) 
is the only systemic therapy with documented efficacy in the manage- 
ment of ACC and is recommended by currently available guidelines 
(Berruti et al., 2012b; Fassnacht et al., 2018). Over the past years, 
several drugs have been tested against ACC but discouraging results 
have been observed up to now (Fassnacht et al., 2018; Ferrari et al., 
2016). Although preclinical results obtained in the NCI–H295R cell line 
demonstrated a cytotoxic and antisecretive effect of paclitaxel (Fallo  
et al., 1996, 1998), paclitaxel and docetaxel failed to demonstrate a 
relevant activity in 2 published clinical trials (Berruti et al., 2012a,b; 
Urup et al., 2013). The histopathological characteristics and at the level 
of drug accessibility significantly influence the sensitivity and re- 
sistance of the tumors to taxanes. Resistance to taxanes is a multi- 
factorial phenomenon that mainly involves P-gp expression, but also 
includes mutation and alteration in the microtubule. Moreover, other 
mechanisms have been suggested, such as reactive oxygen species 
production, activation of DNA repair systems, non-coding RNA and 
epigenetics (Pucci et al., 2018). Interestingly, adrenal gland physiolo- 
gically express P-gp (Uhlén et al., 2015), and its maintenance in ACC 
cells has been proposed as one of the possible causes of resistance of 
ACC to both paclitaxel and docetaxel (Jordan and Wilson, 2004). To 
overcome this mechanism, the semisynthetic taxane cabazitaxel was 
developed on the basis of its poor affinity for P-gp (Galsky et al., 2010) 
and its high lypophilicity (Vrignaud et al., 2013; Azarenko et al., 2014). 
The present study demonstrates that cabazitaxel exerts a relevant 
cytotoxic activity in ACC cell lines and in patient-derived primary cell 
cultures, although with different sensitivity, that can be due to the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. Cabazitaxel promoted apoptotic cell death and cell cycle arrest in NCI–H295R cells. 
A) NCI–H295R cells were treated for different time with cabazitaxel at its IC50 and then 
stained with AO/EtBr. Viable (green), apoptotic (yellow) and necrotic (red) cells were scored 
under a confocal laser-scanning microscope. Bars represent the percentage of each cell colour 
vs the total  number of cell/field. Magnification, 10x. At least 6 fields were analyzed  for each 
experimental point. ***p < 0.001 vs untreated apoptotic (yellow) cells. 
B) NCI–H295R cells were treated with cabazitaxel at its IC50, stained with propidium 
iodide and analyzed for DNA content by flow cytometry. Histograms representative of one 
out of three experiments were shown in the figure. 
 
peculiar phenotype of each cell type. 
Indeed, cabazitaxel demonstrated higher cytotoxicity compared to 
the first-generation taxanes, both in ACC cell lines NCI–H295R and in 
HAC-15 cells (a subclone of NCI–H295R cells) and in 5 out of 6 primary 
cell cultures. In particular, cabazitaxel, within nanomolar concentra- 
tions, displayed a cytotoxicity close to 100% after 4 days of treatment in 
the ABCB1-expressing NCI–H295R cells and this effect was independent 
of P-gp. It should be underlined that ACC03, ACC08 and ACC16 ap- 
peared to be partially resistant to each taxane, although cabazitaxel was 
the most efficacious. Cabazitaxel and other taxanes displayed a rela- 
tively low cytotoxicity against the ACC cell line MUC-1, which has been 
established from a patient with disease progression to EDP-M. Similar 
results were obtained in the ACC06-1 primary cell culture, which de- 
rived from a patient who underwent surgery for hepatic metastasis after 
EDP-M therapy. These results suggest that additional resistance me- 
chanisms may have been activated in these ACC cells. Unfortunately, 
due to the limited cell availability, we could not perform additional 
experiments on this primary cell culture. In ACC29 and ACC32 cells 
primary cells, cabazitaxel was more efficacious and potent than pacli- 
taxel and docetaxel, with concentration-response curves similar to  that 
obtained in NCI–H295R cells. Concerning results obtained with the 
primary cell cultures, it is noteworthy that the different tumor cell 
characteristics, together with the size of the biological sample and the 
dispersion experiment yield, allowed us to obtain sometimes a work- 
able number of cells, i.e. with ACC239 and ACC32 primary cultures, 
  
 
 
Fig. 8. Effect of cabazitaxel on the expres- 
sion of AKT and p-AKT proteins by Western 
blot technique. NCI–H295R cells were ex- 
posed to the IC50 value of cabazitaxel for 1 
day. A) A representative WB is shown. B) 
Densitometric analysis of blots of protein of 
interest were normalized to the corre- 
sponding GAPDH levels. Results were ob- 
tained from three different biological re- 
plicates. Bars represent the mean ± S.E.M. 
*P < 0.01 vs untreated cells. 
 
 
 
 
 
while in other cases, we could perform each taxane concentration-re- sponse curve only twice, although always in triplicate. The ACC pri- mary cell 
cultures were thus an interesting approach to evaluate the in vitro drug sensitivity, however, we are aware of the limit of this model. As expected, 
inhibition of P-gp activity/expression significantly increased the cytotoxicity induced by paclitaxel in ABCB1-expressing cells. Conversely, the 
cytotoxic effect of cabazitaxel was independent of P-gp protein expression as both the pharmacological inhibition using the P-gp inhibitor tariquidar 
and ABCB1 gene expression knock-down did not affect the drug cytotoxicity. 
The combination of the poor affinity for P-gp together with the high lipophilicity of cabazitaxel suggest that the drug may easily accumulate in 
ACC cells. This point however is speculative and needs to be ex- tensively studied. 
Cabazitaxel in combination with mitotane induced in ACC cells a cytotoxicity that presented an additive/light synergic effect. This effect could 
have an interesting clinical implication, as the therapeutic potential of the combination can be obtained at low doses of each drug, thus ameliorating 
the toxicity profile. A limit of this  combination could be the fact that cabazitaxel is mainly metabolized by hepatic CYP3A4/5, and mitotane is a 
CYP3A4/5 inducer. Up to now, however, no cabazitaxel-mitotane interactions are reported (Micromedex Solutions, 2019), although this possibility 
cannot be excluded. Furthermore, clinical efficacious mitotane concentrations usually are obtained after several weeks to months of treatment 
(Terzolo et al., 2013). A slow onset of mitotane activity is thus a main limitation, that can possibly be overcome by the contemporary administration 
of cabazitaxel, with a faster onset of action. 
Several studies indicate that taxanes are potent promoters of apoptosis in cancer cells, but their cytotoxic mechanisms are not yet fully 
understood (Ganansia-Leymarie et al., 2003). Continuous research on the mechanisms of action of cancer drugs, included taxanes, re- vealed a 
scenario more complex that initially expected (Komlodi- Pasztor et al., 2011). Furthermore, the alteration of cytoskeleton in- duced by taxanes may 
have an impact of a number of intracellular activities such as protein trafficking, signal transduction, cell migration and cell division. Our results are 
in line with this hypothesis, as we observed that cabazitaxel induced cytotoxicity in ACC cells by an early activation of apoptosis and the increase of 
cell cycle inhibitors, that lead to cell cycle arrest. However, in ACC cells, we cannot exclude a role of cabazitaxel in the modification of intracellular 
physiology, with an impact on intracellular metabolism or receptor trafficking, as it has been demonstrated in prostate cancer (Fitzpatrick and de 
Wit, 2014). This point is of interest and deserves to be deeply investigate in a dedicated study. 
In detail, in NCI–H295R cells, cabazitaxel early activated different apoptotic pathways and cell cyle arrest. We observed a significant in- crease 
of cytochrome C, an early event implying the loss of the mi- tochondrial integrity (Wong, 2011), and an increase of pro-apoptotic proteins, such as 
Bad and Bax, involved in the intrinsic apoptotic pathway, as well as the increase of death receptors, markers of the extrinsic pathway. The induced 
apoptotic stimulus resulted in the in- crease of apoptotic cell detection up to 4 days. Cabazitaxel caused also    an arrest of the cell cycle, with the 
accumulation of NCI–H295R cells in the S-phase, modulated by the increase of proteins, such as p21/CIP1/ CDNK1A and p27/Kip1. Indeed, 
p21/CIP1/CDNK1A is a universal cdk inhibitor  that  blocks  progression  through  all  stages  of  G1/S  (Dutto  et al., 2015; Fragni et al., 2016), while  
overexpression  of  27/Kip1  blocks progression through S phase (Noomhorm et al., 2014). We ob- served that cabazitaxel exposure activated as well some 
anti-apoptotic proteins and molecules involved in adaptative response to stress, that could represent an attempt of cells to protect themselves against the 
apoptotic insult. Finally, the PI3K/Akt pathway was possibly involved    in the cytotoxic effects of cabazitaxel in NCI–H295R cells. The PI3K/Akt 
signaling network is crucial to different physiological process, that in- clude cell cycle progression (Potter et al., 2002), differentiation (Lopez- Carballo et 
al., 2002), transcription (Brazil et al., 2004), translation (Hanada et al., 2004) and apoptosis (Lei et al., 2005) in a wide range of human cells. Akt is an 
essential component of the PI3K pathway and a gain of function in Akt can lead to uncontrolled cell proliferation and resistance to apoptosis, that 
are both hallmarks of oncogenic transfor- mation (Li et al., 2012). According to previous studies, and in line with our results, Akt dephosphorylation 
can activate Bad protein to trigger apoptotic cascades and upregulate p21 and p27 proteins inducing cell cycle arrest (Li et al., 2012; She et al., 
2005). A criticism raised by our results was the increase of the S15-p53, as it is known that NCI–H295R cells express a truncated form of p53, 
lacking the COOH terminus. p53 directly regulates the transcription of over 500 genes and indirectly regulates many additional genes and thereby 
controls diverse cellular processes, however intriguing results come from the TP53 knock-out mice, where the “expected” spontaneous development  
  
 
 
 
 
of tumors did not occur (reviewed in Aubrey et al., 2018). The significance of our finding cannot be find at this time and this result deserves to be 
deeply in- vestigated. 
In conclusion, the results of this study demonstrated for the first time that cabazitaxel is active against ACC cells in vitro and provided the 
rationale for the design a clinical trial entitled: “Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After 
Previous Chemotherapy Lines” (CabACC study, EUDRACT2017- 001591, ClinicalTrials.gov Identifier: NCT03257891), which has been 
approved by the local Ethic Committee of Brescia (Italy) and is cur- rently recruiting. 
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